As a result, the CAR exhibits strong in vivoin-vivo and in vitro tumor-killing capacity against EGFR-vIII mutant or EGFR-overexpressing tumor cells, but maintains low toxicity to EGFR normally expressed cells (43). Here, COX8A is linked to neoplasm.